---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-003197"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:30:04.212981+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corbus receives FDA IND clearance for CRB-601; Nasdaq grants extension to May 8, 2024

## Summary
- FDA cleared IND for CRB-601, a TGFβ blocking monoclonal antibody targeting integrin αvβ8.
- Phase 1 study first participant enrollment expected in H1 2024; pre-clinical data showed enhanced anti-tumor activity.
- Nasdaq granted extension until May 8, 2024 to regain compliance with $2.5M stockholders' equity requirement, conditional on capital raise.
- Stockholders' equity was $311,016 as of Sep 30, 2023, below the $2.5M minimum; alternative standards not met.
- Failure to regain compliance by May 8, 2024 may lead to delisting; company has right to appeal.

## SEC filing metadata
- accession: 0000950170-24-003197
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017024003197/0000950170-24-003197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017024003197/crbp-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-003197
- JSON: https://secwatch.observer/filing/0000950170-24-003197.json
- Plain text: https://secwatch.observer/filing/0000950170-24-003197.txt

## Key facts
- Listing & Compliance Notices
  Corbus Pharmaceuticals Holdings, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of $311,016, as reported in the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2023, was below the required minimum of $2.5 million, and because, as of November 9,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017024003197/0000950170-24-003197-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.